Downstream Process Optimization for Improved Product Recovery

Late-stage downstream process optimization can provide opportunities to improve manufacturing economics without changing the established product quality profile or compromising process performance.

In this case, Protheragen supported a Phase II clinical-stage program during late-stage downstream process optimization. The objective was to replace the existing imported chromatography resin while maintaining consistent product quality, step-wise process yields, and overall process robustness.

Historical process development reports were systematically reviewed to identify the most appropriate optimization direction. A domestically manufactured chromatography resin was subsequently evaluated as a replacement for the imported resin. Following optimization, the individual process-step yields and product quality remained consistent with the original process, while the resin cost was reduced by approximately 40%, providing an opportunity to substantially reduce the manufacturing cost of goods (COGs).

The Challenge

Replacing Chromatography Resin Without Compromising Process Robustness

The key challenge was to replace the existing imported chromatography resin while maintaining:

• Consistent product quality;
• Consistent process-step yields;
• Robust process performance; and
• The established downstream process characteristics.

For a clinical-stage program, changing a key chromatography material during late-stage development requires careful evaluation. A replacement resin needs to provide sufficiently comparable purification performance while avoiding unexpected changes in yield or product quality.

At the same time, the replacement needed to provide a meaningful economic benefit to justify the process change.

Therefore, the optimization objective could be summarized as:

Resin Replacement → Comparable Process Performance → Consistent Product Quality → Lower Manufacturing Cost

Our Strategy

• Review Historical Process Development Reports

The team first reviewed the historical downstream process development reports and existing process knowledge.

This retrospective assessment provided a basis for understanding the established purification process, identifying previously evaluated process parameters, and determining the most appropriate direction for late-stage optimization.

By leveraging historical development data, the team could focus the optimization on a specific process opportunity rather than introducing unnecessary changes across the entire downstream process.

• Identify Resin Replacement as the Optimization Direction

Based on the review of historical development information, chromatography resin replacement was identified as the primary direction for late-stage process optimization.

The existing imported resin was replaced with a domestically manufactured chromatography resin.

The replacement strategy was designed to maintain the performance characteristics of the established purification process while reducing the cost associated with chromatography resin.

Importantly, the evaluation focused not only on the cost of the resin itself but also on whether the replacement could maintain:

• Step-wise process yield;
• Product quality;
• Overall process robustness.

• Evaluate the Replacement Resin Against the Established Process

The replacement resin was evaluated by comparing its process performance with the original imported resin.

The optimized process demonstrated that the yield of each process step and product quality remained consistent with the original process.

This indicated that the resin replacement could achieve the desired cost reduction without requiring a fundamental change to the established downstream purification strategy.

• Maintain Process Robustness

Because the project was conducted at a late clinical development stage, maintaining process robustness was an important consideration.

The resin replacement was therefore evaluated within the context of the existing process rather than solely based on resin cost.

The final selection considered the combined requirements of:

Process Yield + Product Quality + Process Robustness + Resin Cost

This provided a balanced basis for assessing the feasibility of the replacement resin for the established downstream process.

Results

Consistent Process Performance After Resin Replacement

Following optimization, the domestically manufactured chromatography resin demonstrated downstream process performance comparable to the original imported resin.

The yield of each process step remained consistent with the original process, indicating that resin replacement did not result in a meaningful deterioration in step-wise recovery.

At the same time, product quality remained consistent with the original process, supporting the suitability of the replacement resin for the established purification process.

Fig. 1. Comparison of process yields and drug substance quality before and after chromatography resin replacement.

Key Outcomes

Project Outcome

The results demonstrate that a carefully designed multi-step purification strategy can effectively balance impurity clearance, product purity, and process recovery in complex antibody downstream process development.

The project demonstrated that a carefully controlled chromatography resin replacement can provide a practical opportunity for late-stage downstream process optimization.

By reviewing historical process development data and identifying resin replacement as a targeted optimization direction, the team replaced the imported chromatography resin with a domestically manufactured alternative.

Following optimization, process-step yields and product quality remained consistent with the original process, while resin cost was reduced by approximately 40%.

The resulting process provided an opportunity to improve manufacturing economics and reduce COGs without fundamentally changing the established downstream purification process.

Related Services